Active Focal Segmental Glomerulosclerosis Is Associated with Massive Oxidation of Plasma Albumin

Luca Musante,*† Giovanni Candiano,* Andrea Petretto,‡ Maurizio Bruschi,*† Nazzareno Dimasi,§ Gianluca Caridi, * Barbara Pavone,¶** Piero Del Boccio,¶** Monica Galliano,‡‡ Andrea Urbani,¶** Francesco Scolari,‡‡ Flavio Vincenti,§§ and Gian Marco Ghiggeri*

*Laboratory on Pathophysiology of Uremia, †Mass Spectrometry Core Facility, §Laboratory of Molecular Medicine, G. Gaslini Children Hospital, and Renal Child Foundation, Genoa, Department of Biomedical Science, Università degli Studi di Chieti e Pescara, Chieti, ¶Centro Studi sull’Invecchiamento, Fondazione Università “G. D’Annunzio,” Chieti, ¶¶IRCCS-Fondazione Santa Lucia, Rome, ‡‡Department of Biochemistry, University of Pavia, Pavia, and §§Transplant Service, University of California, San Francisco, San Francisco, California

The basic mechanism for idiopathic FSGS still is obscure. Indirect evidence in humans and generation of FSGS by oxidants in experimental models suggest a role of free radicals. In vitro studies demonstrate a main role of plasma albumin as antioxidant, its modification representing a chemical marker of oxidative stress. With the use of complementary liquid chromatography electron spray ionization tandem mass spectrometry (LC-ESI-MS/MS) and biochemical methods, plasma albumin was characterized in 34 patients with FSGS; 18 had received a renal transplant, and 17 had IgM mesangial deposition. Patients with FSGS that was in remission or without recurrence after transplantation had normal plasma albumin, and the same occurred in patients with primary and secondary nephrites and with chronic renal failure. In contrast, patients with active FSGS or with posttransplantation recurrence had oxidized plasma albumin. This finding was based on the characterization of albumin Cys 34 with an mass-to-charge ratio of 511.71 in triple charge that was consistent with the formation of a cysteic acid carrying a sulfonic group (alb-SO₃⁻). The exact mass of albumin was increased accordingly (+48 Da) for incorporation of three oxygen radicals. Direct titration of the free sulfhydryl group 34 of plasma albumin and electrophoretic titration curves confirmed loss of free sulfhydryl group and formation of a fast-moving isoform in all cases with disease activity. This is the first demonstration of in vivo plasma albumin oxidation that was obtained with an adequate structural approach. Albumin oxidation seems to be specific for FSGS, suggesting some pathogenetic implications. Free radical involvement in FSGS may lead to specific therapeutic interventions.

FSGS is a degenerative disease of the kidney that is characterized by focal accumulation of extracellular matrix in glomeruli. It is a heterogeneous condition that includes different variants (1–4), possible genetic background (5), and variable response to drugs that modify long-term outcome (6). The basic lesion ranges from minimal glomerular involvement to segmental-global glomerulosclerosis that probably represents an evolutionary stage in patients who are unresponsive to drugs (1,4). On clinical grounds, FSGS usually has an abrupt onset with heavy proteinuria, hypoalbuminemia, and frequent progression to renal failure. Notwithstanding some recent advances on the characterization of genes that are responsible for congenital FSGS (7–11), little is known of the pathogenesis of the idiopathic form. The disease typically presents clinical recurrences after infectious episodes and a remarkable percentage of 30 to 50% of patients who have FSGS and receive renal allograft have posttransplantation recurrence (12–15). Abnormal T cell responses, have been suggested to be involved in the pathogenesis of the idiopathic form and in posttransplantation recurrences but remain poorly defined and lack specificity (16). On the basis of the rapid posttransplantation recurrence, an implication of circulating plasma factors that persist over time and modify glomerular permeability to proteins long has been suspected (13,14). Unfortunately, the identification and the characterization of the circulating factors have been elusive (17,18), and, more recently, other pathogenetic mechanisms have been proposed (19).

In an attempt to elucidate the pathogenesis of FSGS, we embarked on a proteomics approach to study plasma proteins in these patients. Our previous studies in patients with FSGS (20) demonstrated massive oxidation of plasma albumin, resulting in modification of the structure of the protein. We
proposed that massive oxidation plays a role in the pathogenesis of the proteinuria that is associated with FSGS. In this study, we devised a mass spectrometry technique for analysis of native plasma albumin that is more reproducible and abolished the need for chemical manipulation of the protein. The structural analysis of albumin then was extended to a wide cohort of patients with nephrotic syndrome and to patients with posttransplantation recurrence of FSGS. Children who had other forms of primary and secondary glomerulonephritis and/or chronic renal failure (end-stage renal failure [ESRF]) were presented with florid proteinuria and nephrotic syndrome at the time of the enrollment; four had been in stable remission in the previous 2 yr. Eleven patients of the group with mesangial IgM deposits were presenting florid proteinuria and nephrotic syndrome at the time of the study, and the remaining six were in stable remission. The general criteria for enrollment were (1) availability of a clear histology diagnosis on the basis of accepted criteria and (2) absence of familiarity and/or relevant mutations of slit diaphragm genes (NPHS2, ACTN4). Nephrotic syndrome was defined by the presence of florid proteinuria >40 mg/h per m². Renal biopsies were processed by standard procedures for light microscopy, immunofluorescence studies, and electron microscopy. Clinical and pathologic features (e.g., gender, age at onset of proteinuria, treatment, evolution toward renal failure, renal transplant) are reported in Tables 1 and 2. Patients with FSGS and IgM and with active proteinuria were receiving treatment with steroids alone (at variable dosages) or in association with cyclosporin and with angiotensin-converting enzyme inhibitors (ACEi). Steroids were given in a starting dosage of prednisolone 2 mg/kg followed by a gradual taper (21). Cyclosporin was administered at 5 mg/kg starting dosage, followed by dosage adjustment to maintain cyclosporin serum levels between 50 and 100 ng/ml (6). Six patients of the stable remission groups with either FSGS or IgM were still receiving cyclosporin; ACEi was used in one. Eighteen children with FSGS had developed ESRF and had received a cadaver renal transplant. Immununosuppression therapy in these patients included tacrolimus or cyclosporin, mycophenolate mofetil, and steroids. Fourteen patients of this cohort had posttransplantation recurrence of proteinuria that was treated with plasmapheresis (1.5-l plasma exchange with albumin as the unique replacement protein) in all but one patient and was associated with cyclophosphamide 2 mg/kg for 2 mo in one patient.

**ESRF.** Nine patients who had chronic renal failure and were undergoing various treatments were enrolled. One was a child (patient 1), two were adolescents (patients 2 and 9), and six were young adults who developed ESRF for various reasons (Table 3). The therapeutic approach was hemodialysis in six cases, and two patients were maintained on a conservative treatment.

**Membranous Glomerulonephritis.** Eight patients had received a diagnosis of membranous nephropathy and were all in the proteinuric phase of the disease (Table 4). All but one were adults and were presenting a variable degree of proteinuria from 1 to 8 g/d. Patients with membranous glomerulonephritis (MGN) were receiving steroids as single drug (1 to 2 mg/kg) or in combination with immune suppressors (22); in some cases, ACEi (ramipril 5 to 8 mg/m²) had been associated.

**Membrane Proliferative Glomerulonephritis.** Four patients had a histology diagnosis of membrane proliferative glomerulonephritis (MPGN) that presented with proteinuria, hematuria, and normal renal function without arterial hypertension (Table 4). All were receiving prednisolone (1 mg/kg) for at least 2 mo.

**IgA.** Five patients had a recent diagnosis of IgA in the absence of relevant proteinuria. Only one was treated with steroids; in three cases, it was used in a scheme with ACEi (Table 4).

**Normal Control Subjects.** The control group consisted of 18 healthy adult control subjects. In all cases plasma was obtained in the morning after an overnight fast. In patients with posttransplantation recurrence, plasma was obtained at the onset of proteinuria and during the follow-up. Morning fresh urine was collected in sterile condition without additive and frozen at −80°C within 1 h. Plasma was frozen within 1 h and was maintained at −80°C under vacuum. Appropriate informed consent was obtained from all patients in the study.

**Purification of Albumin from Healthy Donors and Patients**

Albumin was purified from plasma of healthy donors and patients with FSGS by preparative continuous monodimensional PAGE electrophoresis (total acrylamide concentration = 4 to 12%) in native conditions with 2-mm gel spacers. All purification steps were performed in a native condition to prevent structural modifications according to Margolis and Kenrick (23). One milliliter of serum was applied to gel, and electrophoresis was run in Tris-borate-EDTA (80/90/2.5 mM) for 12 h with 16 mA at 12°C. Albumin was desorbed from acrylamide by gentle pestle and was maintained in PBS at 4°C for 24 h with two changes of the solution.

**Liquid Chromatography Electron Spray Ionization Tandem Mass Spectrometry (LC-ESI-MS/MS) for Tryptic Digest Characterization**

Albumin after purification was delipidated first in a methanol-acetonitrile phosphate (1:12:1) with gentle agitation at room temperature overnight and then was digested by trypsin. Trypsin was added at an enzyme substrate ratio of 1:30 (wt/wt) in a solution of 100 mM ammonium bicarbonate and 1 mM CaCl₂ (pH 8.5). After overnight incubation at 37°C, the reaction was stopped with formic acid to pH 2.

All mass spectrometric measurements were performed using an LTQ linear trap mass spectrometer (Thermo Electron, San Jose, CA) coupled to an HPLC Surveyor (Thermo Electron) and equipped with a Jupiter C18 column 250 × 1 mm (Phenomenex, Torrance, CA). Peptides were eluted from the column using an acetonitrile gradient, 5% B for 6 min followed by 5 to 90% B within 109 min (eluent A: 0.1% formic acid in water; eluent B: 0.1% formic acid in acetonitrile) at a flow rate of 50 μl/min. The column effluent was directed into the electrospray source.
The spray voltage was 5.0 kV. The capillary of ion trap was kept at 200°C, and the voltage was kept at 2.85 V. Spectra were acquired in automated MS/MS mode: Each full MS scan (in the range 400 to 1800 mass-to-charge ratio [m/z]) was followed by five MS/MS of the most abundant ions; mass that had been analyzed more than two times this way was automatically taken up into an exclusion list for 30 s. Computer analysis of peptide MS/MS spectra was performed using Bioworks software, version 3.2 (Thermo Electron) and searched against an ALB protein database. Peptide MS/MS assignments were filtered according to the following criteria: cross-correlation (Xcorr) /H11350 1.9 for the singly charged ions, Xcorr /H11350 2.2 for doubly charged ions, and Xcorr /H11350 3.7 for triply charged ions; peptide probability /H11349 0.001; change in correlation value (ΔCn) /H9004 0.1; and percentage of ions ≥30%. For all protein, two missed cleavages was allowed.

ESI-MS for Exact Mass

Albumin-containing solutions were injected manually (5 μl) into an on-line flow, using a CapLC system (Micromass, Waters, Milford, MA) coupled with a nano-ESI-Q-TOF (quadrupole–time-of-flight) instrument (Micromass, Waters). The sample was eluted at 1 μl/min on a C4 precolumn LC-Packings, 300 μm inner diameter × 20 mm. Elution was achieved isocratically by H2O/ACN 50/50 both with 0.1% TFA and directed into a mass spectrometer equipped with a nano-Lock-Spray source. A 2500- and 50-V tension was applied to the PicoTip capillary (PicoTip Emitter, tip 10 μm; New Objective, Woburn, MA) and cone voltage, respectively, and the positive ion mode for ion scan experiment was used to monitor the 700- to 2200-m/z range. Data analysis was performed usingMasslynx version 4.0 (Micromass/Waters). The data collected were examined for multiply charged protein.

Table 1. Clinical and biochemical parameters in 33 children with idiopathic nephrotic syndrome subdivided according to renal pathology

<table>
<thead>
<tr>
<th>Patient</th>
<th>Gender</th>
<th>Age (yr)</th>
<th>Age at Onset (yr)</th>
<th>Proteinuria (g/24 h)</th>
<th>Serum Creatinine (mg/dl)</th>
<th>Serum Albumin (g/dl)</th>
<th>Therapy</th>
</tr>
</thead>
<tbody>
<tr>
<td>FSNGS</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1</td>
<td>M</td>
<td>9</td>
<td>1</td>
<td>7</td>
<td>0.4</td>
<td>1</td>
<td>St/ACEi</td>
</tr>
<tr>
<td>2</td>
<td>M</td>
<td>11</td>
<td>7</td>
<td>3</td>
<td>1.1</td>
<td>2.2</td>
<td>CsA</td>
</tr>
<tr>
<td>3</td>
<td>M</td>
<td>10</td>
<td>4</td>
<td>4</td>
<td>1.1</td>
<td>1.5</td>
<td>St</td>
</tr>
<tr>
<td>4</td>
<td>M</td>
<td>10</td>
<td>4</td>
<td>4</td>
<td>0.8</td>
<td>1.7</td>
<td>St</td>
</tr>
<tr>
<td>5</td>
<td>M</td>
<td>15</td>
<td>5</td>
<td>5</td>
<td>1.2</td>
<td>1.1</td>
<td>St</td>
</tr>
<tr>
<td>6</td>
<td>M</td>
<td>5</td>
<td>3</td>
<td>2</td>
<td>1.2</td>
<td>2.1</td>
<td>St/ACEi</td>
</tr>
<tr>
<td>7</td>
<td>M</td>
<td>2</td>
<td>2</td>
<td>4</td>
<td>0.8</td>
<td>1.2</td>
<td>CsA/ACEi</td>
</tr>
<tr>
<td>8</td>
<td>M</td>
<td>20</td>
<td>7</td>
<td>3</td>
<td>2.6</td>
<td>2</td>
<td>St</td>
</tr>
<tr>
<td>9</td>
<td>F</td>
<td>7</td>
<td>6</td>
<td>4</td>
<td>1.2</td>
<td>2</td>
<td>CsA</td>
</tr>
<tr>
<td>10</td>
<td>F</td>
<td>10</td>
<td>5</td>
<td>4</td>
<td>1</td>
<td>1.2</td>
<td>St</td>
</tr>
<tr>
<td>11</td>
<td>F</td>
<td>11</td>
<td>3</td>
<td>5</td>
<td>1.5</td>
<td>1.1</td>
<td>CsA/ACEi</td>
</tr>
<tr>
<td>12</td>
<td>F</td>
<td>9</td>
<td>1</td>
<td>3</td>
<td>0.7</td>
<td>2.1</td>
<td>St</td>
</tr>
<tr>
<td>13</td>
<td>M</td>
<td>14</td>
<td>2</td>
<td>0.4</td>
<td>0.7</td>
<td>4.4</td>
<td>CsA</td>
</tr>
<tr>
<td>14</td>
<td>M</td>
<td>12</td>
<td>1</td>
<td>0.1</td>
<td>0.3</td>
<td>4.4</td>
<td>CsA</td>
</tr>
<tr>
<td>15</td>
<td>M</td>
<td>22</td>
<td>7</td>
<td>0.1</td>
<td>0.5</td>
<td>4</td>
<td>ACEi</td>
</tr>
<tr>
<td>16</td>
<td>M</td>
<td>8</td>
<td>2</td>
<td>0.2</td>
<td>0.5</td>
<td>4.8</td>
<td>CsA</td>
</tr>
</tbody>
</table>

IgM

<table>
<thead>
<tr>
<th>Patient</th>
<th>Gender</th>
<th>Age (yr)</th>
<th>Age at Onset (yr)</th>
<th>Proteinuria (g/24 h)</th>
<th>Serum Creatinine (mg/dl)</th>
<th>Serum Albumin (g/dl)</th>
<th>Therapy</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>M</td>
<td>5</td>
<td>1</td>
<td>8</td>
<td>0.8</td>
<td>0.9</td>
<td>CsA</td>
</tr>
<tr>
<td>2</td>
<td>M</td>
<td>7</td>
<td>3</td>
<td>2</td>
<td>0.2</td>
<td>1.7</td>
<td>CsA</td>
</tr>
<tr>
<td>3</td>
<td>M</td>
<td>9</td>
<td>8</td>
<td>5</td>
<td>0.7</td>
<td>1.4</td>
<td>St/ACEi</td>
</tr>
<tr>
<td>4</td>
<td>M</td>
<td>3</td>
<td>2</td>
<td>5</td>
<td>0.3</td>
<td>2.2</td>
<td>St/ACEi</td>
</tr>
<tr>
<td>5</td>
<td>M</td>
<td>10</td>
<td>4</td>
<td>6</td>
<td>0.6</td>
<td>1.3</td>
<td>CsA</td>
</tr>
<tr>
<td>6</td>
<td>M</td>
<td>4</td>
<td>1</td>
<td>4</td>
<td>0.4</td>
<td>1.3</td>
<td>CsA</td>
</tr>
<tr>
<td>7</td>
<td>M</td>
<td>8</td>
<td>4</td>
<td>7</td>
<td>0.4</td>
<td>1.6</td>
<td>St</td>
</tr>
<tr>
<td>8</td>
<td>M</td>
<td>6</td>
<td>1</td>
<td>3</td>
<td>0.6</td>
<td>1</td>
<td>St</td>
</tr>
<tr>
<td>9</td>
<td>F</td>
<td>6</td>
<td>6</td>
<td>8</td>
<td>0.7</td>
<td>1.3</td>
<td>St</td>
</tr>
<tr>
<td>10</td>
<td>F</td>
<td>8</td>
<td>2</td>
<td>2</td>
<td>0.3</td>
<td>1.3</td>
<td>St/ACEi</td>
</tr>
<tr>
<td>11</td>
<td>F</td>
<td>16</td>
<td>4</td>
<td>5</td>
<td>0.5</td>
<td>1.3</td>
<td>CsA/ACEi</td>
</tr>
<tr>
<td>12</td>
<td>M</td>
<td>20</td>
<td>5</td>
<td>0.2</td>
<td>0.4</td>
<td>4.5</td>
<td>St</td>
</tr>
<tr>
<td>13</td>
<td>M</td>
<td>14</td>
<td>4</td>
<td>0.1</td>
<td>0.3</td>
<td>4.3</td>
<td>CsA</td>
</tr>
<tr>
<td>14</td>
<td>M</td>
<td>12</td>
<td>3</td>
<td>0.2</td>
<td>0.5</td>
<td>4.4</td>
<td>CsA</td>
</tr>
<tr>
<td>15</td>
<td>M</td>
<td>12</td>
<td>2</td>
<td>0.2</td>
<td>0.5</td>
<td>4.3</td>
<td>CsA</td>
</tr>
<tr>
<td>16</td>
<td>F</td>
<td>8</td>
<td>1</td>
<td>0.1</td>
<td>0.2</td>
<td>4.4</td>
<td>–</td>
</tr>
<tr>
<td>17</td>
<td>F</td>
<td>16</td>
<td>3</td>
<td>0.1</td>
<td>0.7</td>
<td>4.1</td>
<td>–</td>
</tr>
</tbody>
</table>

aTen patients were evaluated during stable remission of nephrotic syndrome. induced by drugs; in these, plasma had been collected after at least 6 mo of normal urine. ACEi, angiotensin-converting enzyme inhibitor; CsA, cyclosporine; St, steroids.
spectra, which then were integrated to provide a single combined spectrum for the protein injected. A maximum entropy deconvolution algorithm (MaxEnt1) was used to deconvolute multiply charged spectra and produce molecular mass spectra.

Electrophoretic Titration Curves

For electrophoretic titration curves, we used total plasma in anticoagulant citrate dextrose. Titration was performed according to Bruschi et al. (24). Both methods for electrophoresis runs and calculations have been described previously (24,25).

Table 2. Clinical parameters in 18 children who had idiopathic FSGS and developed ESRF and received a renal graft.

<table>
<thead>
<tr>
<th>Patient No.</th>
<th>Gender</th>
<th>Onset (yr)</th>
<th>ESRF (yr)</th>
<th>Transplantation (yr)</th>
<th>Days for Recurrence</th>
<th>Therapy</th>
<th>Outcome</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>M</td>
<td>4.2</td>
<td>6</td>
<td>7</td>
<td>1</td>
<td>PL</td>
<td>Stable proteinuria</td>
</tr>
<tr>
<td>2</td>
<td>F</td>
<td>4.3</td>
<td>7</td>
<td>8</td>
<td>7</td>
<td>–</td>
<td>Stable proteinuria</td>
</tr>
<tr>
<td>3</td>
<td>M</td>
<td>10.5</td>
<td>14</td>
<td>15</td>
<td>1</td>
<td>PL</td>
<td>Remission</td>
</tr>
<tr>
<td>4</td>
<td>F</td>
<td>4.2</td>
<td>12</td>
<td>13</td>
<td>9</td>
<td>PL</td>
<td>Remission</td>
</tr>
<tr>
<td>5</td>
<td>M</td>
<td>9.6</td>
<td>11</td>
<td>13</td>
<td>15</td>
<td>PL</td>
<td>Remission</td>
</tr>
<tr>
<td>6</td>
<td>M</td>
<td>12.3</td>
<td>30</td>
<td>34</td>
<td>15</td>
<td>PL</td>
<td>Stable proteinuria</td>
</tr>
<tr>
<td>7</td>
<td>F</td>
<td>13.7</td>
<td>18</td>
<td>19</td>
<td>3</td>
<td>PL</td>
<td>Frequent recurrence</td>
</tr>
<tr>
<td>8</td>
<td>M</td>
<td>0.6</td>
<td>4</td>
<td>5</td>
<td>22</td>
<td>PL</td>
<td>Remission</td>
</tr>
<tr>
<td>9</td>
<td>M</td>
<td>2.2</td>
<td>4</td>
<td>6</td>
<td>1</td>
<td>PL</td>
<td>Remission</td>
</tr>
<tr>
<td>10</td>
<td>M</td>
<td>14</td>
<td>14</td>
<td>16</td>
<td>30</td>
<td>PL/Cy</td>
<td>ESRF</td>
</tr>
<tr>
<td>11</td>
<td>M</td>
<td>11</td>
<td>11</td>
<td>15</td>
<td>600</td>
<td>PL</td>
<td>Normal function</td>
</tr>
<tr>
<td>12</td>
<td>F</td>
<td>36</td>
<td>45</td>
<td>50</td>
<td>30</td>
<td>PL</td>
<td>Stable proteinuria</td>
</tr>
<tr>
<td>13</td>
<td>F</td>
<td>28</td>
<td>32</td>
<td>33</td>
<td>1</td>
<td>PL</td>
<td>ESRF</td>
</tr>
<tr>
<td>14</td>
<td>F</td>
<td>5</td>
<td>28</td>
<td>32</td>
<td>4</td>
<td>PL</td>
<td>Nephrectomy</td>
</tr>
</tbody>
</table>

No recurrence
1. F 5.2 8 10 – – –
2. F 3.0 6 9 – – –
3. F 6.3 7 8 – – –
4. M 5.2 16 17 – – –

*Fourteen patients of this cohort presented recurrence of proteinuria and were treated with a combination of plasmapheresis and cyclophosphamide. The other four patients had stable and prolonged good outcome. Cy, cyclophosphamide; ESRF, end-stage renal failure; PL, plasmapheresis.

Table 3. Clinical and biochemical parameters in nine patients with chronic renal failure from various renal pathologies

<table>
<thead>
<tr>
<th>ESRF Gender Age (yr) Renal Pathology</th>
<th>Serum Creatinine (mg/dl)</th>
<th>Serum Albumin (g/dl)</th>
<th>HD/PD</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 F 2 Dysplasia</td>
<td>3</td>
<td>4</td>
<td>–</td>
</tr>
<tr>
<td>2 M 12 ARPKD</td>
<td>4</td>
<td>3.5</td>
<td>–</td>
</tr>
<tr>
<td>3 M 32 Terminal kidney</td>
<td>–</td>
<td>3.2</td>
<td>HD</td>
</tr>
<tr>
<td>4 M 26 Reflux nephropathy</td>
<td>–</td>
<td>4.1</td>
<td>HD</td>
</tr>
<tr>
<td>5 M 24 Reflux nephropathy</td>
<td>–</td>
<td>4.2</td>
<td>HD</td>
</tr>
<tr>
<td>6 M 24 TIN</td>
<td>–</td>
<td>3.8</td>
<td>HD</td>
</tr>
<tr>
<td>7 F 21 LES</td>
<td>–</td>
<td>4.1</td>
<td>HD</td>
</tr>
<tr>
<td>8 M 20 ARPKD</td>
<td>–</td>
<td>4.2</td>
<td>HD</td>
</tr>
<tr>
<td>9 M 14 FSGS</td>
<td>–</td>
<td>3.5</td>
<td>HD</td>
</tr>
</tbody>
</table>

*Seven patients had developed ESRF and were undergoing hemodialysis (HD). Two children presented severe renal lesions but were still on a conservative treatment. ARPKD, autosomal recessive polycystic kidney disease; LES, lupus erythmatosus systemic; PD, peritoneal dialysis; TIN, tubulointerstitial nephropathy.

“*In Gel*” Determination of Free SH Accessibility

Free SH group titration in plasma albumin was done with the maleimide-PEO₂-Biotin (biotinyl-3-maleimidopropionamidyl-3,6-dioxactanediame) assay (Pierce, Rockford, IL) according to the manufacturer’s instructions. After reaction with maleimide-PEO₂-Biotin, plasma proteins first were separated in monodimensional polyacrylamide gels performed according to Laemmli (26) without mercapto-ethanol. After electrophoresis (total acrylamide concentration = 5 to 16%; degree of cross-link = 2.67%) reactivity of SH groups with maleimide was allowed at pH 6.5 for 2 h at 37°C. Streptavidin that was conjugated with
horseradish peroxidase was used to determine biotin incorporation with 2-(4'-hydroxyazobenzene)-benzoic acid using the EZ Biotin Quantitation Kit (Pierce) at 500 nm with correction for the amount of albumin as determined by Coomassie R-250. A calibration curve that consisted of four dilutions of the same serum with known concentration of albumin was used as standard. Specificity of the maleimide dye for the free SH group of Cys 34 was demonstrated by preventing the binding with methyl-methanethiosulfonate that specifically binds this group at pH 5.

**Albumin Degradation In Vitro**

A total of 100 µg of purified albumin was incubated at 37°C for 16 h with 0.1 µg/ml (wt/vol) of bovine trypsin in a medium that contained 50 mM Tris-HCl (pH 7.8) and 5 mM CaCl₂. The digestion was stopped by addition of Laemmli reducing sample buffer (10 mM Tris-HCl [pH 8.8], 1% [wt/vol] SDS, 1 mM EDTA, 20% [vol/vol] glycerol, and 5% [vol/vol] β-mercaptoethanol) (26). After 1 h, the samples were loaded on 8 to 18% (wt/vol) gradient SDS-PAGE and run at 45 mA at 12°C. Gel was fixed with 40% (vol/vol) ethanol and 10% (vol/vol) acetic acid and stained by silver nitrate.

**Albumin Gene DNA Sequence**

Genomic DNA was extracted from patient blood. The 14 coding exons of human albumin gene and their intron-exon junctions were PCR-amplified with specific primer pairs as already described by Watkins *et al.* (27). Amplicons were purified by Exo-SAP-IT (Amersham Bioscience, Milan, Italy) and directly subjected to direct sequencing (ABI 3100; Applera, Milan, Italy).

**Glutathione Assay**

Reduced glutathione (GSH) levels were determined in plasma and in red blood cells after trichloroacetic precipitation (28% wt/vol). GSH was determined by dithio-bis (2-nitrobenzolic acid) at 412 nm with correction with a blank reagent and using free cysteine as the standard (28).

**Statistical Analyses**

Simple statistical tests based on one-way ANOVA and χ² test were used to verify differences in free SH titration and N-A transition among different cohorts of patients. Data are mean ± SEM.

**Results**

**Chemical and Structural Characterization of Plasma Albumin in FSGS**

The structural approach to plasma albumin in FSGS was done originally in seven patients, using LC-ESI-MS/MS analysis after reduction and alkylation of purified albumin (20). This approach is not readily applicable for extensive analysis, because the sulfonic group at Cys 34 that is generated upon oxidation is a stable end product in the native protein but may undergo further rearrangements during alkylation (personal observation by G.C.). Therefore, we devised a new proteomic approach to plasma albumin that was based on characterization by LC-ESI-MS/MS of trypsin digestion products of the native protein that are more stable then the alkylated products and gave highly reproducible results. Proteomic analysis of plasma albumin now was extended to 12 patients with FSGS, five with the idiopathic form and seven with posttransplantation recurrence of the disease. In the first step, albumin was purified in nondenaturing conditions using preparative electrophoresis in native gels giving a mean recovery yield >90%. Fine structure analysis by LC-ESI-MS/MS and determination of the exact mass by ESI-MS protein analysis then was repeated in all patients.

**LC-ESI-MS/MS.** The spectrum of albumin after digestion with trypsin indicated the presence of a parent fragment m/z 827.96 (KALVLIIFQYLYQQC₃₉⁵PFEDHVK.L) in the triply charged state. The m/z 827.96 compound was studied by MS/MS showing the presence of an m/z 511.71 ion in triple charge that was consistent with a sequence in which the Cys 34 brings three additional oxygen residues, indicating oxidation of the SH to cysteic acid (+48; Figure 1). Control albumin was characterized by the absence of the m/z 827.96 ion in triple charge. In Table 5 are reported the sequences with relative Xcorr and ΔCn of the MS/MS characterization of the m/z 827.96 ion in the cohort of patients with primary nephrotic syndrome and post-transplant recurrence. Xcorr and ΔCn were in all cases highly significant, confirming the presence of a cysteic group in position 34.

**Table 4. Clinical and biochemical parameters in patients with different primary renal pathologies involving the glomerulus**

<table>
<thead>
<tr>
<th>Pathology</th>
<th>n</th>
<th>Gender</th>
<th>Age (yr)</th>
<th>Onset (yr)</th>
<th>Proteinuria (g/d)</th>
<th>Serum Creatinine (mg/dl)</th>
<th>Serum Albumin (g/dl)</th>
<th>Class</th>
<th>Therapy: St/CsA/ACEi</th>
</tr>
</thead>
<tbody>
<tr>
<td>MGN</td>
<td>8</td>
<td>5 M, 3 F</td>
<td>39 (12 to 55)</td>
<td>36 (10 to 53)</td>
<td>6.0 (1.0 to 8.0)</td>
<td>1.1 (0.5 to 1.4)</td>
<td>1.5 (1.2 to 2.0)</td>
<td>Class I: 1</td>
<td>7/0/6</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Class II: 2</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Class III: 4</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Class IV: 1</td>
<td></td>
</tr>
<tr>
<td>MPG</td>
<td>4</td>
<td>3 M, 1 F</td>
<td>14 (8 to 16)</td>
<td>9 (6 to 12)</td>
<td>2.5 (0.5 to 4.0)</td>
<td>0.8 (0.6 to 1.0)</td>
<td>3.2 (2.8 to 4.0)</td>
<td>–</td>
<td>4/0/4</td>
</tr>
<tr>
<td>A</td>
<td>5</td>
<td>3 M, 2 F</td>
<td>42 (18 to 56)</td>
<td>25 (12 to 35)</td>
<td>&lt;0.5</td>
<td>0.9 (0.5 to 1.2)</td>
<td>3.8</td>
<td>Class II: 3</td>
<td>1/0/3</td>
</tr>
<tr>
<td>Class II: 3</td>
<td>1/0/3</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Class III: 2</td>
<td>1/0/3</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Class IV: 1</td>
<td>1/0/3</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*Overall, 17 patients were enrolled. They were selected among the most frequent causes of glomerular diseases that cause nephrotic syndrome (MGN), intermediate proteinuria (membrane proliferative glomerulonephritis [MPGN]) and hematuria (IgA).
ESI-MS. Analysis of the exact mass of plasma albumin was used to confirm the result of the structural analysis in a large cohort of patients. In all patients with FSGS, the bulk of plasma albumin presented an exact mass of 66.555 kD, whereas this isoform was only minimally detected in normal plasma in which the major band presents a mass of 66.507 kD (data not shown).

**Biomarkers of Albumin Oxidation in Patients with FSGS/IgM**

On the basis of sulfonic transformation, the free SH of Cys 34 of albumin should not be titrated any more and could become a specific marker of oxidation. We devised a method for direct “in gel” determination of free Cys 34 in plasma that could be used in screening analysis. In this technique, the free Cys of albumin was targeted by maleimide-PEO₂ biotin, and the reaction then was revealed by streptavidin. This assay was extended, with the analysis of N-A transition by electrophoretic titration curves (24), to the whole cohort of patients. Overall, 23 patients with primary FSGS/IgM and florid proteinuria and 14 who were presenting posttransplantation recurrence of proteinuria were studied. Ten patients with FSGS/IgM in stable remission and four who received a renal transplant but were free from recurrence represented the negative control group for disease activity.

**Cys 34 Titration.** The results are given in Figure 2, the former reporting an example of in gel titration in a selection of patients from each separate clinical subset as above. It is evident the lack of albumin band in the PEO₂-maleimide gel in patients with proteinuria (see boxes in Figure 2). Figure 3 reports extensive results that confirm a marked decrease of Cys 34 titration in all patients with FSGS and IgM in both pre- and posttransplantation phases compared with normal people and with MGN with some differences within categories. In particular, patients with active FSGS and IgM had markedly lower levels than in the remission phase (0.43 ± 0.12 and 0.230 ± 0.42 U; P < 0.003 and P < 0.001, respectively); patients with posttransplantation recurrence showed only mildly lower levels than in patients with no recurrence (0.27 ± 0.04 versus 0.71 ± 0.19). Normal people and other nephrotic patients with MGN had instead the same concentration (normal control subjects 2.75 ± 0.33; MGN 2.48 ± 0.67). For other categories of renal diseases, see below. Overall, in patients with active FSGS/IgM, Cys 34 seems massively oxidized, whereas during the remission phase, a normal albumin pool is reconstituted.

**N-A Transition.** The rationale and the technique to define N-A transition have been described extensively (24). Briefly, changes in electrical charge were determined by an electrophoretic titration curve (24), to the whole cohort of patients. Overall, 23 patients with primary FSGS/IgM and florid proteinuria and 14 who were presenting posttransplantation recurrence of proteinuria were studied. Ten patients with FSGS/IgM in stable remission and four who received a renal transplant but were free from recurrence represented the negative control group for disease activity.

**Figure 1.** Mass spectrometry analyses of plasma albumin in FSGS. Example of LC-ESI-MS/MS spectrum of the Cys 34 tryptic fragments of albumin from a patient with FSGS. Albumin that was purified from the patient showed, after digestion with trypsin, the parent fragments mass-to-charge ratio (m/z) 511.7 in triply charged state, indicating the formation of a cysteic residue in place of the sulphydryl group in position 34 of albumin. Analysis of control albumin did not reveal the formation of the m/z 511.7 fragment because of lack of ionization of nonoxidized free sulphydryl groups (SH).

**Table 5.** Sequence of the m/z 827.96 ion deriving from trypsin fragmentation of albumin that was purified from patients with FSGS

<table>
<thead>
<tr>
<th>Patient</th>
<th>Peptide</th>
<th>Xcorr</th>
<th>Δ Cn</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>K.ALVLIAFAQYLQQC*PFEDHVKL</td>
<td>6.35</td>
<td>0.97</td>
</tr>
<tr>
<td>2</td>
<td>K.ALVLIAFAQYLQQC*PFEDHVKL</td>
<td>6.55</td>
<td>0.99</td>
</tr>
<tr>
<td>3</td>
<td>K.ALVLIAFAQYLQQC*PFEDHVKL</td>
<td>6.03</td>
<td>0.95</td>
</tr>
<tr>
<td>4</td>
<td>K.ALVLIAFAQYLQQC*PFEDHVKL</td>
<td>4.85</td>
<td>0.99</td>
</tr>
<tr>
<td>5</td>
<td>K.ALVLIAFAQYLQQC*PFEDHVKL</td>
<td>5.95</td>
<td>0.98</td>
</tr>
<tr>
<td>6</td>
<td>K.ALVLIAFAQYLQQC*PFEDHVKL</td>
<td>6.55</td>
<td>0.97</td>
</tr>
<tr>
<td>7</td>
<td>K.ALVLIAFAQYLQQC*PFEDHVKL</td>
<td>6.02</td>
<td>0.95</td>
</tr>
<tr>
<td>8</td>
<td>K.ALVLIAFAQYLQQC*PFEDHVKL</td>
<td>4.78</td>
<td>0.98</td>
</tr>
<tr>
<td>9</td>
<td>K.ALVLIAFAQYLQQC*PFEDHVKL</td>
<td>6.31</td>
<td>0.99</td>
</tr>
<tr>
<td>10</td>
<td>K.ALVLIAFAQYLQQC*PFEDHVKL</td>
<td>5.87</td>
<td>0.98</td>
</tr>
<tr>
<td>11</td>
<td>K.ALVLIAFAQYLQQC*PFEDHVKL</td>
<td>4.58</td>
<td>0.93</td>
</tr>
<tr>
<td>12</td>
<td>K.ALVLIAFAQYLQQC*PFEDHVKL</td>
<td>5.74</td>
<td>0.97</td>
</tr>
</tbody>
</table>

*In the case of normal albumin, no ions with this m/z could be detected in triple charge. MS/MS in triple charge of this ion demonstrated the presence of a cysteic acid residue with m/z 511.7. Xcorr and ΔCn were in all cases highly significant and probative for the chemical characterization above. C*, cysteic acid; Cn, correlation value; MS/MS, tandem mass spectrometry; m/z, mass-to-charge ratio; Xcorr, cross-correlation.
phoretic technique that measures changes in isoelectric point at any given pH from 4 to 9. This technique also gives an estimate of the amount of the protein with a charge change that is inferred from the formation of isoform with different electrophoretic behavior. In all of the cases studied, the variation in electrical charge involved 100% of the protein, and Figure 4A shows an example of this change. Overall, the screening for N-A transition confirmed the data on SH titration with some difference for patients without posttransplantation recurrence. In fact, N-A transition was common to all patients with active FSGS and IgM and to those with posttransplantation recurrence, whereas, in the absence of proteinuria, in patients without posttransplantation, recurrence and in patients with MGN, a normal electrophoretic behavior was reconstituted. The percentage of patients with N-A transition in the various groups is illustrated in Figure 4C and clearly shows a difference among categories. Table 6 reports the mean ± SD of ionization parameters reproducing experimental curves of 10 normal control subjects and patients with proteinuria, according to the Linderström-Lang equation. Considering the parameters reported in Table 6, this difference can be attributed to the presence of a sulfonic group in position 34 of the sequence that modifies our original assumption reported previously (24).

Figure 2. Titration of the Cys 34 free SH groups of albumin in FSGS, IgM, and membranous glomerulonephritis (MGN). Titration of albumin free SH 34 by a direct “in gel” technique that uses PEO2-maleimide-biotin (top) as a specific label. According to this method, plasma proteins first are labeled with PEO2-maleimide-biotin and then are separated by monodimensional electrophoresis in nondenaturing conditions. After separation, the reaction is developed with streptavidin. Albumin from healthy people showed PEO2-maleimide staining corresponding to albumin (arrows), whereas albumin of patients with FSGS had no staining, indicating absence of a free SH that is unique in albumin at position 34 of the sequence (boxes). To prove specificity of the maleimide staining for the free SH, one sample had been treated previously with methyl-methanethiosulfonate (MMTS) that specifically blocked the free SH and prevented the maleimide binding.

Figure 3. Estimation of Cys 34-free SH group of albumin in the whole cohort of patients with FSGS, IgM, and MGN. Results are expressed as arbitrary unit of biotin per milligram of albumin. A calibration curve with several dilutions of the same plasma was prepared to obtain a confidence limit for linearity of the assay.

Titration of Albumin Cys 34 in Patients with ESRF and with Other Glomerular Diseases

A few other groups of patients with different renal diseases were enrolled and used for demonstrating the specificity for FSGS of sulfonation of albumin Cys 34. The following groups of patients were enrolled (Tables 3 and 4): (1) Nine patients with chronic renal failure, two of whom were still on a conservative regimen; (2) four children with primary MPGN; and (3) five patients with IgA. In all cases, a normal titration of Cys 34 by PEO2-maleimide was observed. The results presented in Figure 5 show a typical pattern of albumin staining with the dye. It was found that maleimide staining, in particular, is specific for the free SH group of Cys 34 because was abolished by prein-
cubation of the protein with methyl-methanethiosulfonate at pH 5.

**Albumin Gene DNA Sequence**

The 14 coding exons of human albumin gene and their intron-exon junctions were sequenced in all patients who were enrolled in the study. In all cases, normal sequence was found, excluding a genetic basis for altered oxidation.

**Susceptibility to Digestion by Trypsin**

Because the antioxidation effect of albumin has been considered a suicidal reaction that modifies susceptibility to digestion by common proteases, albumin was purified from plasma of four patients with idiopathic FSGS and four with posttransplantation recurrence and submitted to mild digestion with trypsin (see the Materials and Methods section).

The results reported in Figure 6 demonstrate the formation of fragments in the majority of affected cases, confirming the original assumption (lanes f through n). Normal albumin was not digested following the same conditions (lanes a through e).

**GSH in Plasma and in Erythrocytes**

GSH levels were determined in plasma and in red blood cells of proteinuric patients with FSGS and in control subjects. Levels were slightly decreased in patients with active nephrotic syndrome compared with control subjects in both plasma (8.1 ± 0.2 versus 8.4 ± μmol/L) and in red blood cells (6.8 ± 0.8 versus 7.5 ± 0.8 nmol/mg hemoglobin), but the difference did not reached statistical significance because of the low number of cases.

Table 6. Ionization parameters of healthy and oxidized albumin calculated according to Linderström-Lang equation

<table>
<thead>
<tr>
<th>Groups</th>
<th>Healthy Albumin</th>
<th>Oxidized Albumin</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>n° pK° m</td>
<td>n° pK° m</td>
</tr>
<tr>
<td>α-COOH</td>
<td>1 3.8 ± 0.2</td>
<td>1 3.8 ± 0.3</td>
</tr>
<tr>
<td>γ-COOH</td>
<td>96 4.00 ± 0.02</td>
<td>96 4.00 ± 0.03</td>
</tr>
<tr>
<td>Tylic</td>
<td>1 8.0 ± 0.3</td>
<td>1 8.0 ± 0.2</td>
</tr>
<tr>
<td>Phenolic</td>
<td>18 10.2 ± 0.2</td>
<td>18 10.2 ± 0.3</td>
</tr>
<tr>
<td>Imidazole</td>
<td>2 6.24 ± 0.01</td>
<td>2 6.23 ± 0.01</td>
</tr>
<tr>
<td>α-Amino</td>
<td>1 7.80 ± 0.02</td>
<td>1 7.80 ± 0.02</td>
</tr>
<tr>
<td>ε-Amino</td>
<td>59 10.4 ± 0.4</td>
<td>59 10.4 ± 0.5</td>
</tr>
<tr>
<td>Guanidyl</td>
<td>24 &gt;12</td>
<td>24 &gt;12</td>
</tr>
<tr>
<td>Sulfonic</td>
<td>0 –</td>
<td>1 6.23 ± 0.01</td>
</tr>
<tr>
<td>pI</td>
<td>4.79 ± 0.01</td>
<td>4.68 ± 0.01</td>
</tr>
</tbody>
</table>

n°, number of ionizable amino acid; pK°, pK° medium of ionizable amino acid.

Figure 4. Electrophoretic titration curves for neutral to acid N-A transition. (A) Example of electrophoretic titration curve of a plasma sample from a patient with FSGS and for comparison of normal plasma stained with Coomassie R-250. The two proteins migrate as a single and homogeneous band throughout the pH range: Between 4 and 4.5 and between 7 and 9, they overlap, whereas in the pH range between 4.5 and 7, oxidized albumin migrates with a more acid charge. (B) Theoretical electrophoretic curve of albumin in which a cystic group replaces a free sulfhydryl residue. According to the Linderström-Lang theory, this acid charge shift fits with the introduction of a sulfonic acid group in the molecule. Determination of albumin charge along a stable pH gradient was done according the procedure described by Bruschi et al. (24). (C) Percentage of patients with N-A transition in patients with nephrotic syndrome and different clinical activity. Presence and/or absence of fast albumin in the pH range 4.5 and 7 was evaluated in all patients that was defined in positive cases as N-A transition. Bars indicate the percentage of patients with N-A transitions in different study cohorts.
Discussion

The underlying mechanism of antioxidant response in living systems has been investigated widely for a long time. Several aspects related to antioxidant response in human plasma remain unresolved because, despite comparable or even increased exposure to oxidants, plasma levels of major intracellular antioxidant molecules such as GSH and related enzymes are much lower than in the intracellular compartment (0.006 versus 0.75 mM/L). Studies that used in vitro models of oxidation convincingly indicated that plasma albumin is involved in plasma antioxidant activity by means of the unique free sulfhydryl groups of Cys 34 that is transformed into a sulfonic group by oxidation. In vitro models also suggest that the intermediate of the reaction is a sulfenic (SOH-alb) that in vivo may rapidly react with free GSH to form nonmercapto albumin or form dimers of the protein (29). Overall, this reaction should involve 20 to 25% of albumin that is the amount of nonmercapto plus dimeric albumin in plasma. Even if in vitro studies furnish a solid chemical background to a participation of albumin into the antioxidant response in plasma, evidence that albumin oxidation takes place in vivo has never been reported, with the exception of scattered reports of partial albumin oxidation in ESRF (30) and diabetes that had been obtained with indirect techniques (31,32). Studies in patients with ESRF are of particular interest because they show the increase of nonmercaptoalbumin that should represent the product of reaction of free plasma thiols such as GSH and/or homocysteine with the sulfenic derivative of albumin. The quota of sulfenic albumin in patients with ESRF is estimated to represent less than the 5% of total albumin. In this study, we demonstrate for the first time that plasma albumin in patients with active FSGS undergoes massive and stable oxidation with chemical modification of the unique free SH of Cys 34 to a sulfonic group (SO3⁻/H11002) that is an end product of the reaction. This change involves some relevant alterations of the protein with formation of an adduct with 48-Da molecular weight, changes of the net charge as a result of additional negative residues, and loss of free SH titration. Therefore, in vivo plasma oxidation produces a more stable derivative than the one described in in vitro models, and, most important, SO3⁻-alb does not dimerize but undergoes proteolysis. This later event may be considered a suicidal effect that results in albumin removal from plasma. Accordingly, many albumin fragments can be detected in urine of patients with FSGS. As a whole, these data demonstrate that oxidation of albumin in FSGS occurs in vivo, and this is the first demonstration of what seems to be a crucial physiologic process. Overall, the process of oxidation of albumin in FSGS seems substantially different from oxidation that is reported in patients with ESRF because, as already discussed, it mainly involves only the formation of an instable intermediate in this condition. According to the literature on the topic (31,32), the amount of sulfonic end product in patients with ESRF is approximately 5% of total albumin and is under the limit of sensitivity of the maleimide assay. Lack of observation of this peculiar structural modification on the basis of a direct spectroscopic approach in other cohorts of patients with primary and secondary glomerulonephritis with and without nephrotic syndrome and in young adults with ESRF suggests, therefore, a good degree of specificity for FSGS.

This key observation leads to two considerations. The first is that albumin, as a result of the high plasma levels, is the major antioxidant substance in plasma and is higher than other antioxidants. In other words, the molar level of the free SH of Cys
34 of albumin is higher than free GSH by a factor of 100 (0.8 versus 0.008 mM). Second, massive oxidation of plasma albumin implicates new pathogenic mechanisms in FSGS related to oxidation. In this view, data deriving from the determination of biomarkers of albumin oxidation (SH titration and N-A transition) suggest some clinical correlations: (1) In pretransplantation patients, oxidation is associated with proteinuria, whereas in patients with stable remission, there is a clear trend to normalization; (2) the effect of the nephrotic syndrome per se can be ruled out on the basis of data on patients with MGN; and (3) patients with posttransplantation recurrence also present the same signs of albumin oxidation that are attenuated in absence of recurrence. Lack of complete normalization of free SH in patients in stable relapse and in those who do not have a recurrence could suggest presence of oxidants at lower levels, but we cannot readily exclude that albumin in patients with FSGS/IgM have a stable reduction in antioxidation potential. This is a central point because an altered response of albumin to oxidation could represent a potential trigger of renal toxicity. However, albumin gene sequence in patients with FSGS did not reveal any mutants or sequence variants, ruling out the possibility of a primary defect involving albumin structure. The finding of massive oxidation of albumin in patients with active FSGS also suggests that free radicals are produced in excess in these patients. Several literature data on both human and experimental FSGS strongly support the implication of free radicals. In fact, practically all animal models of nongenetic FSGS are based on free radical generation. They include puromycin and Adriamycin nephrosis in rats and Mvp 17−/− mice (33–37). Renal infusion of H2O2 also induces proteinuria in rats and upregulates the expression of factors such as C/EBP homology protein (GADD 153) that also are upregulated in human FSGS and rat puromycin nephrosis (38). The Adriamycin model is of particular interest because the quinone structure of the molecule allows a direct participation in redox reaction (39,40) and may act directly as a free radical.

Few data on free radical generation during nephrotic syndrome are available in humans. However, increased oxidation for inherited defects that are associated with coenzyme Q deficiency as in the case of CoQ2 mutations produces renal lesions that resemble FSGS (41). Increased peroxidation of membrane lipids and consumption of intraerythrocyte GSH in children with FSGS also support an implication of free radicals (28,42); however, these changes are only indirect and reflect peroxidation by lipophilic substances that probably are not involved here. In this context, a central point is the type of oxidant involved. Several studies that investigated the structural effect of various oxidants on plasma proteins in vitro (43,44) clearly indicated that oxidation of thiol groups is specific of N-chloramines and more stable than other similar compounds and probably propagate damage from the source of HOCl. Their half-life, however, is in the order of a few minutes, and we have no chance to demonstrate high levels of N-chloramines in plasma of patients. Analysis of sulfonation of the free Cys 34 SH may serve as a good way to reveal their effect, and we propose a wider utilization for clinical and experimental studies.

The observation of massive oxidation of albumin in FSGS and the possibility to have readily available laboratory assays may lead to preemptive therapy before the development of massive proteinuria. Our finding also lends support to the current use of plasmapheresis for recurrence of FSGS. The success of plasmapheresis in inducing remission of proteinuria in patients with recurrent FSGS may be due to exchange of albumin (replacement of oxidized with normal albumin) rather than the assumed removal of a circulating permeability factor.

**Conclusion**

These data demonstrate massive oxidation of plasma albumin in patients with FSGS that induces stable sulfonation of Cys 34. Oxidation of albumin is associated with disease activity and posttransplantation recurrence of proteinuria. The analytical methods that we have described allow rapid determination of albumin oxidation and may lead to prompt therapeutic intervention.

**Acknowledgments**

This work was conducted with the financial support of the Italian Ministry of Health and of a grant from the Renal Child Foundation. We also acknowledge Fondazione Mara Wilma e Bianca Querci for the financial support of the project “Nuove evoluzioni sulla multifattorialità della sindrome nefrosica.”

Data were discussed critically with Prof. R. Gusmano, and we acknowledge her role. The manuscript was revised by A. Capurro.

**Disclosures**

None.

**References**

9. Shih NY, Li J, Karpitskii V, Nguyen A, Dustin ML, Kana-
drome requires a coordinated interplay between cathepsin L and a3 integrin. J Biol Chem 279: 34827–34832, 2004
drome requires a coordinated interplay between cathepsin L and a3 integrin. J Biol Chem 279: 34827–34832, 2004
drome requires a coordinated interplay between cathepsin L and a3 integrin. J Biol Chem 279: 34827–34832, 2004
puromycin aminonucleoside and adriamycin nephrosis. Clin Sci (Lond) 78: 283–293, 1990


